About PedMAb

The PedMAb1 study is a Phase 1 study, and one of the first paediatric HIV prevention studies to investigate the safety and pharmacokinetics of two long-acting broadly neutralizing antibodies (VRC07-523LS and CAP256V2LS) to eliminate the risk of breastmilk transmission of HIV.

Breastfeeding is a key child survival strategy; hence the importance of eliminating the risk of HIV transmission through breastmilk.

PedMAb1 is being conducted as a partnership between the SAMRC, IRCCS Ospedale San Raffaele, Milan, Italy, University of Montpellier, France, Wits Health Consortium and University of Bergen, Norway, with funding from EDCTP and the SAMRC.

The study is being conducted in the SAMRC Chatsworth Clinical Research Site (CRS) situated on the premises of the RK Khan hospital and surrounding delivery facilities.

Read More